Liquid chromatography–tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction

Fanny Leenhardt; Matthieu Gracia; Catherine Perrin; Claudia Muracciole-Bich; Bénédicte Marion; Celine Roques; Marie Alexandre; Nelly Firmin; Stephane Pouderoux; Litaty Mbatchi; Céline Gongora; William Jacot; Alexandre Evrard

doi:10.1016/j.jpba.2020.113438

Journal articles

Liquid chromatography–tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction

Fanny Leenhardt ¹ Matthieu Gracia Catherine Perrin Claudia Muracciole-Bich Bénédicte Marion ² Celine Roques ³ Marie Alexandre ⁴ Nelly Firmin ⁵ Stephane Pouderoux ⁴ Litaty Mbatchi ⁶ Céline Gongora William Jacot Alexandre Evrard

1 UNH - Unité de Nutrition Humaine

2 IBMM - Institut des Biomolécules Max Mousseron [Pôle Chimie Balard]

3 GeT PlaGe - GeT PlaGe, Genotoul

4 ICM - Institut du Cancer de Montpellier

5 Département d'oncologie Médicale

6 Laboratoire de Biochimie [CHRU Nîmes]

Keywords : CDK4/6 inhibitor Drug-drug interactions HPLC-MS/MS Metastatic breast cancer Therapeutic drug monitoring

Document type :

Journal articles

Domain :

Life Sciences [q-bio]

Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-03003807
Contributor : Céline Gongora <>
Submitted on : Monday, January 4, 2021 - 1:49:39 PM
Last modification on : Tuesday, February 23, 2021 - 3:26:08 PM

Main text JPBA .pdf

Files produced by the author(s)

Liquid chromatography–tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction

Files

Identifiers

Collections

Citation

Export

Metrics

80

49

Liquid chromatography–tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction

Files

Identifiers

Collections

Citation

Export

Share

Metrics

80

49